Different expression levels of interleukin-36 in asthma phenotypes

Table 2 Clinical characteristics and sputum cell numbers in asthma inflammatory phenotypes

Variable	EA	NA	PA	MA	P value
Number	23	9	24	6
Age, yrs	50.48 ± 17.33	59.44 ± 12.36	54.83 ± 14.80	64.00 ± 10.58	0.192
Male, n (%)	13 (56.5)	1 (11.1)	11 (45.8)	2 (33.3)	0.129
BMI, kg/m²	23.48 ± 3.99	24.89 ± 4.05	24.42 ± 3.62	24.00 ± 3.52	0.762
Ex-smoker, n (%)^a	10 (43.5)	5 (55.6)	12 (50)	2 (33.3)	0.801
Pre-bronchodilator FEV1, L^a	1.93 ± 0.92	1.53 ± 0.83	1.74 ± 0.73	1.78 ± 0.58	0.670
Post-bronchodilator FEV1, L^a	2.21 ± 0.97	1.86 ± 0.84	1.98 ± 0.65	2.08 ± 0.61	0.644
Post-bronchodilator FVC, L^a	3.20 ± 0.96	3.08 ± 0.96	2.87 ± 0.63	2.96 ± 0.65	0.616
Post-bronchodilator FEV1/pred (%)	72.53 ± 21.33	64.37 ± 25.94	77.16 ± 26.99	80.81 ± 17.17	0.495
Post-bronchodilator FVC/pred (%)	88.78 ± 14.25	85.24 ± 21.31	91.47 ± 22.21	94.90 ± 20.09	0.761
Post-bronchodilator FEV1/FVC (%)	67.14 ± 14.56	57.92 ± 13.68	68.90 ± 14.16	71.06 ± 15.74	0.227

The cells were tested in the sputum samples. Data are expressed as mean ± SD or median (IQR). Data were analyzed by ANOVA or Kruskal–Wallis test. Abbreviations as in Table 1
^aAdjusted for age

ISSN: 1710-1492